

Application Serial No. 09/838,821
Amendment dated May 31, 2005
Response to Office Communication of February 28, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1. (previously presented) A method of inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with an inhibitor of Janus family kinase 3 (JAK-3).

Claim 2. (previously presented) The method of claim 1, wherein the cells are exposed to ara-C, a topoisomerase II inhibitor, ultraviolet radiation, an alkylating agent, or ionizing radiation.

Claim 3. (previously presented) The method of claim 1, wherein the cells are exposed to ultraviolet radiation or ionizing radiation.

Claim 4. (cancelled)

Claim 5. (cancelled)


Claim 6. (previously presented) The method of claim 2, wherein the contacting occurs prior to the exposure.

Claim 7. (previously presented) The method of claim 2, wherein the contacting occurs after the exposure.

Claim 8. (previously presented) The method of claim 1, wherein the JAK-3 inhibitor is a protein.

Claim 9. (previously presented) The method of claim 1, wherein the JAK-3 inhibitor is a compound of formula I:

Application Serial No. 09/838,821
 Amendment dated May 31, 2005
 Response to Office Communication of February 28, 2005



wherein

X is HN, R₁₁N, S, O, CH₂, or R₁₁CH;

R₁₁ is hydrogen, (C₁-C₄)alkyl, or (C₁-C₄)alkanoyl;

R₁-R₈ are each independently hydrogen, hydroxy, mercapto, amino, nitro, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, (C₁-C₄)alkylthio, or halo; wherein two adjacent groups of R₁-R₅ together with the phenyl ring to which they are attached may optionally form a fused ring; and further wherein the ring formed by the two adjacent groups of R₁-R₅ may optionally be substituted by 1, 2, 3, or 4 hydroxy, mercapto, amino, nitro, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, (C₁-C₄)alkylthio, or halo; and

R₉ and R₁₀ are each independently hydrogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, halo, or (C₁-C₄)alkanoyl; or R₉ and R₁₀ together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

Claim 10. (cancelled)

Claim 11. (cancelled)

Claim 12. (cancelled)


Claim 13. (cancelled)

BEST AVAILABLE COPY

Application Serial No. 09/838,821
Amendment dated May 31, 2005
Response to Office Communication of February 28, 2005

Claim 14. (previously presented) A therapeutic method for preventing or treating a pathological condition in a mammal wherein c-jun activation is implicated and inhibition of c-jun activation is desired, comprising administering to a mammal an inhibitor of JAK-3.

Claim 15. (previously presented) The method of claim 14, wherein the JAK-3 inhibitor is a compound of formula I:



wherein

X is HN, R₁₁N, S, O, CH₂, or R₁₁CH₂

R₁₁ is hydrogen, (C₁-C₄)alkyl, or (C₁-C₄)alkanoyl;

R_1 - R_8 are each independently hydrogen, hydroxy, mercapto, amino, nitro, (C_1 - C_4)alkyl, (C_1 - C_4)alkoxy, (C_1 - C_4)alkylthio, or halo; wherein two adjacent groups of R_1 - R_5 together with the phenyl ring to which they are attached may optionally form a fused ring; and further wherein the ring formed by the two adjacent groups of R_1 - R_5 may optionally be substituted by 1, 2, 3, or 4 hydroxy, mercapto, amino, nitro, (C_1 - C_4)alkyl, (C_1 - C_4)alkoxy, (C_1 - C_4)alkylthio, or halo; and

R₉ and R₁₀ are each independently hydrogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, halo, or (C₁-C₄)alkanoyl; or R₉ and R₁₀ together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

BEST AVAILABLE COPY